Phio Pharmaceuticals Corp Stock Price, News & Analysis

Phio Pharmaceuticals (NASDAQ: PHIO) announced a presentation at the 9th Annual CAR-TCR Summit in Boston, MA, showcasing its INTASYL self-delivering RNAi technology. The presentation, titled 'INTASYL Self-Delivering RNAi: A Flexible Platform to Improve Adoptive Cell Therapy,' will be given by Melissa Maxwell on September 17th. INTASYL is designed to enhance cell potency and yield in Adoptive Cell Therapy, potentially offering a more effective approach for cancer treatment. The technology aims to make immune cells more effective in killing tumor cells through gene silencing. This presentation highlights Phio's efforts to advance its innovative platform in the competitive field of cell therapy.

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical stage biotech company, will participate in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Robert Bitterman will present on the company's INTASYL siRNA gene silencing technology, which aims to enhance immune cells' ability to kill tumor cells.

The presentation will cover:

• INTASYL technology overview
• Associated patents and intellectual property
• Ongoing Phase 1b clinical trial of PH-762, Phio's lead INTASYL compound

Phio's presentation will be streamed online starting September 9th at 7:00 AM ET. The management team will also be available for one-on-one meetings during the conference.

Phio Pharmaceuticals (NASDAQ: PHIO), a clinical stage biotech company specializing in INTASYL® siRNA gene silencing technology, has announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event is scheduled for Thursday, September 5, 2024, at 12 PM EDT.

Robert Bitterman, CEO and Chairman of the Board, will present on behalf of Phio Pharmaceuticals. The presentation will include a live Q&A session. Stakeholders, investors, and interested individuals are invited to register and attend this live event. A replay will be available on the Renmark Financial Communications website.

Phio's INTASYL® technology is designed to enhance the effectiveness of immune cells in killing tumor cells, positioning the company at the forefront of innovative cancer treatments.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) reported its Q2 2024 financial results and provided a business update. Key highlights include:

1. Positive safety recommendation for PH-762 Phase 1b trial, with no dose-limiting toxicities.

2. Addition of a fifth clinical trial site for the PH-762 study.

3. New patent granted in South Korea for INTASYL compounds targeting aging skin disorders.

4. Warrant exercise agreements resulting in $3.1 million gross proceeds.

5. Completion of a 1-for-9 reverse stock split.

6. Regained compliance with Nasdaq's minimum bid price requirement.

7. Appointment of Robert M. Infarinato as CFO.

8. Exploratory collaboration with a global skin care company.

Financial results show cash position of $4.7 million as of June 30, 2024, with decreased R&D and G&A expenses compared to Q2 2023.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced an exploratory collaboration with a leading luxury skin care company to explore opportunities for its patented INTASYL compound in cosmeceutical applications. This collaboration aims to leverage Phio's gene silencing technology for aging skin disorders. CEO Robert Bitterman highlighted the significance of this step in demonstrating INTASYL's versatility across multiple applications.

Phio's INTASYL patent portfolio now includes 77 issued patents covering the silencing of over 25 gene targets in various fields, including dermatology, immuno-oncology, ophthalmology, and viral disorders. The technology is designed to enhance the effectiveness of immune cells in killing tumor cells, with applications for both intratumoral treatment and adoptive cell therapy.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company specializing in INTASYL™ siRNA gene silencing technology, has announced the appointment of Robert M. Infarinato as their new Vice President and Chief Financial Officer, effective August 1, 2024. Infarinato brings over 20 years of financial and accounting leadership experience to the role, where he will serve as Principal Financial Officer overseeing accounting, finance, treasury, investor relations, and administration.

Infarinato's extensive background includes leadership positions in healthcare and pharmaceuticals, such as roles at Abington Health, Rhone Poulenc Rorer, and Pfizer. CEO Robert Bitterman expressed enthusiasm about Infarinato joining the executive team, highlighting his broad experience across multiple financial functions within the healthcare sector.

Phio Pharmaceuticals announced the exercise of certain outstanding warrants, securing approximately $3.1 million in gross proceeds. These warrants, originally priced between $324.00 and $9.72 per share, were exercised at a reduced price of $5.45 per share.

The exercise includes the issuance of new unregistered warrants for additional shares, exercisable at $5.45 per share, with varying terms of five and one-half years and eighteen months. H.C. Wainwright & Co. acted as the exclusive placement agent, and the company plans to use the net proceeds for working capital and general corporate purposes.

The offering, expected to close around July 12, 2024, is contingent on customary closing conditions. The new warrants were issued under an exemption from the registration requirements of the 1933 Act and are available only to accredited investors.

Phio Pharmaceuticals (NASDAQ: PHIO) announced the inclusion of the University of Pittsburgh Medical Center (UPMC) Department of Dermatology as a clinical trial site for its Phase 1b study of PH-762, bringing the total to five participating sites. This trial involves adult patients with cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma and aims to assess the safety and tolerability of PH-762, an INTASYL compound that silences PD-1, enhancing T cell ability to kill cancer cells. The study recently received a positive safety recommendation for dose escalation and is currently enrolling patients for the second cohort. Other participating sites include The George Washington University, Banner MD Anderson Cancer Center, Integrity Research Clinical Associates, and Centricity Research.

Phio Pharmaceuticals (NASDAQ: PHIO) has announced the termination of its share purchase agreement with Triton Funds LP. Initially, this agreement allowed Triton to acquire up to 18.8% of Phio's common stock. Phio is a clinical-stage biotech firm focused on enhancing immune cell efficacy against tumors using its proprietary INTASYL^® siRNA gene-silencing technology.